{"classes":[{"categories":[{"measurements":[{"comment":"Not Applicable - not all participants had an event at time of analysis, max time censored","groupId":"OG000","lowerLimit":"0.2","upperLimit":"NA","value":"22.3"},{"comment":"Not Applicable - not all participants had an event at time of analysis, max time censored","groupId":"OG001","lowerLimit":"0.1","upperLimit":"NA","value":"26.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"374"},{"groupId":"OG001","value":"362"}],"units":"Participants"}],"description":"Overall Survival is equivalent to time to death. For this endpoint, all deaths occurring during the study as a whole until the data cut-off for the survival extension (31st October 2011) are presented (analysis at 75% deaths)","dispersionType":"Full Range","groups":[{"description":"Fulvestrant 250 mg Intramuscular Injection every 28 days","id":"OG000","title":"Fulvestrant 250 mg"},{"description":"Fulvestrant 500 mg Intramuscular Injection every 28 days plus 500 mg on day 14","id":"OG001","title":"Fulvestrant 500 mg"}],"paramType":"MEDIAN","populationDescription":"All randomised patients","reportingStatus":"POSTED","timeFrame":"Median time (in months) from randomisation until death (from any cause),up to 80 months","title":"Overall Survival (OS) - Follow-up","type":"SECONDARY","unitOfMeasure":"months"}